The new study, lead by Richard P. Allen, Ph.D., an associate professor of neurology at the Johns Hopkins University School of Medicine used magnetic resonance imaging to show that glutamate, in addition to dopamine, play a large part in producing a type of hyper-arousal within the brain region known as the thalamus.
Considerable media attention has recently been focused on a San Diego State University study that has reared close to proving that insomnia patients who choose to get off sleeping pills could, quite possibly, be saving their own lives.
ABC World News, NBC and CBS all gave major coverage to this story, but illustrated little on how patients taking drugs like Ambien and Lunesta can actually titrate off of them without suffering severe withdrawal symptoms. This includes a side effect called rebound insomnia, which is described in pharmaceutical literature as not being able to sleep at all for up to seven or more days.
It seems nowadays that everyone has heard of someone who has taken Ambien or Ambien CR and exhibited bizarre behavior while not fully awake.
The maker of Ambien has begun a new ad campaign it hopes will reverse a sales slide triggered by reports that some patients couldn’t recall driving or eating while sleepwalking when using the prescription sleep aid.
The campaign Sanofi-Aventis SA launched Wednesday is likely to be the first salvo in what analysts predict will be a fierce advertising war in the market which has seen sales drop in the aftermath of the negative news. Sanofi’s Ambien is expected to have a new competitor by this summer when Pfizer Inc. and partner Neurocrine Sciences Inc. are slated to debut a new pill.
Copyright 2011 Sleep Recovery Centers, Inc. All rights reserved.
Website Design by EmergingDesigns.com